US2016251340A1PendingUtilityA1

Hydantoin derivatives useful as kv3 inhibitors

62
Assignee: AUTIFONY THERAPEUTICS LTDPriority: Dec 6, 2010Filed: Apr 7, 2016Published: Sep 1, 2016
Est. expiryDec 6, 2030(~4.4 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 25/24A61P 25/18A61P 25/08A61P 25/28A61P 25/20A61P 27/16A61P 25/00A61K 31/4439C07D 405/14C07D 413/14C07D 307/79C07D 317/46C07D 405/12A61K 31/506C07D 413/12C07D 307/94A61K 31/4178
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A compound selected from:
 spiro[1-benzofuran-3,1′-cyclopropan]-4-ol   
       
         
           
           
               
               
           
         
         7-methylspiro[2H-benzofuran-3,1′-cyclopropane]-4-ol 
       
       
         
           
           
               
               
           
         
       
       and
 3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-ol 
 
       
         
           
           
               
               
           
         
         or a salt thereof; or 
         a compound selected from: 
       
       
         
           
           
               
               
           
         
         wherein: 
         X is C or N; 
         Y is C or N; and 
         the group W is selected from: 
       
       
         
           
           
               
               
           
         
       
       or a salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.